+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Continuous Glucose Monitoring Systems Market by Components, Demographics and Adult Population and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027

  • ID: 5118783
  • Report
  • April 2020
  • Region: Global
  • 267 pages
  • Allied Analytics LLP
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • A. Menarini Diagnostics
  • Abbott Laboratories
  • Dexcom Inc.
  • Echo Therapeutics Inc.
  • F. Hoffmann-La Roche Ltd
  • GlySens Incorporated
  • MORE
The global continuous glucose monitoring systems (CGMS) market size was valued at $1,774.2 million in 2019, and is projected to reach $8,844.9 million by 2027, registering a CAGR of 22.0% during the forecast period. Continuous glucose monitoring systems help to manage diabetes by providing real time values of the glucose levels and alert the patient in the event of hypo or hyperglycemia. This helps reduce the probability of any complications related to diabetes. In addition, CGMS offers varied benefits over other glucose monitors in monitoring the blood glucose levels of ICU patients.

Increase in adoption of continuous glucose monitoring systems in home care applications and rise in incidence of diabetes are the major factors that drive market growth. However, reimbursement and stringent regulatory issues in developing countries is anticipated to restrain market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 20.0% from 2020 to 2027. On the contrary, emerging markets are anticipated to offer significant growth opportunities for the market players in the future.

KEY BENEFITS FOR STAKEHOLDERS
  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global digital therapeutics market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS

By Component
  • Sensors
  • Transmitters & Receivers
  • Integrated Insulin Pumps
By Demographics
  • Child Population (≤14 years)
  • Adult Population (>14 years)
By End User
  • Diagnostics/Clinics
  • ICUs
  • Home Healthcare
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Denmark
  • Finland
  • Rest of Europe
  • Asia-Pacific
  • China
  • India
  • Australia
  • Japan
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Venezuela
  • Saudi Arabia
  • South Africa
  • Argentina
  • Rest of LAMEA
KEY MARKET PLAYERS
  • 2MORROW, Inc.
  • Fitbit, Inc. (Twine Health, Inc.)
  • Livongo Health, Inc.
  • Medtronic Plc.
  • OmadaHealth, Inc.
  • Pear Therapeutics, Inc.
  • Proteus Digital Health, Inc.
  • Resmed, Inc. (Propeller Health)
  • Voluntis, Inc.
  • Welldoc, Inc.
The other players in the value chain include (profiles not included in the report):
  • Canary Health Inc.
  • Mango Health Inc.
  • Noom, Inc.
  • Dthera Sciences
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • A. Menarini Diagnostics
  • Abbott Laboratories
  • Dexcom Inc.
  • Echo Therapeutics Inc.
  • F. Hoffmann-La Roche Ltd
  • GlySens Incorporated
  • MORE
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools & Models

Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition
3.2. Need for Glucose Monitoring Systems
3.2.1. Diabetes–A Pandemic
3.2.1.1. Type 1 Diabetes
3.2.1.2. Type-2 Diabetes
3.2.1.3. Prediabetes and Gestational Diabetes Mellitus (Gdm)
3.2.1.4. Gestational Diabetes Mellitus (Gdm)
3.2.1.5. Secondary Diabetes
3.2.1.6. Global Healthcare Expenditure on Diabetes
3.3. Key Findings
3.3.1. Top Investment Pockets
3.3.2. Top Winning Strategies
3.3.3. Value Chain Analysis
3.4. Patent Analysis
3.4.1. Patent Analysis, by Market Participant
3.4.2. U. S. Patent Analysis, by Market Participant
3.4.3. Patent Analysis, by Year
3.5. Market Share Analysis, 2019
3.6. Government Regulations
3.6.1. Fda Regulations (21Cfr820)
3.6.1.1. Objective and Scope of Fda 21Cfr820
3.6.2. Iso Regulations (Iso 13485: 2003)
3.6.2.1. Objective and Scope of Iso 13485: 2003
3.7. Reimbursement Scenario
3.8. Market Dynamics
3.8.1. Drivers
3.8.1.1. Benefits of Cgms Over Poc Glucometers
3.8.1.2. Rise in Incidence of Diabetes Cases
3.8.1.3. Technological Advancements
3.8.2.1. Adverse Effects and Accuracy
3.8.2.2. Reimbursement and Stringent Regulatory Issues
3.8.3. Opportunities
3.8.3.1. High Adoption Rate of Cgms in Home Healthcare and Icus
3.8.3.2. Increase in Product Awareness
3.8.3.3. High Undiagnosed Patient Population
3.8.4. Impact Analyses

Chapter 4: Continous Glucose Monitoring Systems Market, by Component
4.1. Overview
4.1.1. Market Size and Forecast, by Component
4.2. Sensors
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast
4.2.3. Market Analysis, by Country
4.3. Transmitters & Receivers
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast
4.3.3. Market Analysis, by Country
4.4. Integrated Insulin Pumps
4.4.1. Key Market Trends, Growth Factors, and Opportunities
4.4.2. Market Size and Forecast
4.4.3. Market Analysis, by Country

Chapter 5: Continuous Glucose Monitoring Systems Market, by Demographics
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Adult Population (>14 Years)
5.2.1. Market Size and Forecast
5.2.2. Market Analysis, by Country
5.3. Children Population (≤14 Years)
5.3.1. Market Size and Forecast
5.3.2. Market Analysis, by Country

Chapter 6: Continuous Glucose Monitoring Systems Market, by End-user
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Diagnostic Centers/Clinics
6.2.1. Market Size and Forecast
6.2.2. Market Analysis, by Country
6.3. Icus
6.3.1. Market Size and Forecast
6.3.2. Market Analysis, by Country
6.4. Home Healthcare
6.4.1. Market Size and Forecast
6.4.2. Market Analysis, by Country

Chapter 7: Continuous Glucose Monitoring Systems Market, by Region
7.1. Overview
7.1.1. Market Size and Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, and Opportunities
7.2.2. North America Continuous Glucose Monitoring Systems Market Size and Forecast, by Country
7.2.2.2. U. S. Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.2.2.3. U. S. Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.2.2.4. U. S. Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.2.2.6. Canada Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.2.2.7. Canada Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.2.2.8. Canada Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.2.2.10. Mexico Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.2.2.11. Mexico Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.2.2.12. Mexico Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.2.3. North America Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.2.4. North America Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.2.5. North America Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, and Opportunities
7.3.2. Europe Continuous Glucose Monitoring Systems Market Size and Forecast, by Country
7.3.2.1. Germany Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.2.2. Germany Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.2.3. Germany Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3.2.4. France Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.2.5. France Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.2.6. France Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3.2.8. UK Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.2.9. UK Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.2.10. UK Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3.2.12. Spain Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.2.13. Spain Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.2.14. Spain Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3.2.16. Italy Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.2.17. Italy Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.2.18. Italy Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3.2.20. Netherlands Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.2.21. Netherlands Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.2.22. Netherlands Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3.2.23. Norway Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.2.24. Norway Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.2.25. Norway Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3.2.27. Sweden Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.2.28. Sweden Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.2.29. Sweden Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3.2.31. Denmark Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.2.32. Denmark Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.2.33. Denmark Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3.2.35. Finland Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.2.36. Finland Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.2.37. Finland Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3.2.39. Rest of Europe Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.2.40. Rest of Europe Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.2.41. Rest of Europe Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.3.3. Europe Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.3.4. Europe Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.3.5. Europe Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, and Opportunities
7.4.2. Asia-Pacific Continuous Glucose Monitoring Systems Market Size and Forecast, by Country
7.4.2.1. Japan Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.4.2.2. Japan Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.4.2.3. Japan Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.4.2.4. China Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.4.2.5. China Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.4.2.6. China Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.4.2.8. India Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.4.2.9. India Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.4.2.10. India Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.4.2.12. Australia Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.4.2.13. Australia Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.4.2.14. Australia Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.4.2.16. South Korea Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.4.2.17. South Korea Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.4.2.18. South Korea Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.4.2.20. Rest of Asia-Pacific Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.4.2.21. Rest of Asia-Pacific Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.4.2.22. Rest of Asia-Pacific Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.4.3. Asia-Pacific Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.4.4. Asia-Pacific Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.4.5. Asia-Pacific Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.5. LAMEA
7.5.1. Key Market Trends, Growth Factors, and Opportunities
7.5.2. LAMEA Continuous Glucose Monitoring Systems Market Size and Forecast, by Country
7.5.2.1. Brazil Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.5.2.2. Brazil Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.5.2.3. Brazil Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.5.2.5. Saudi Arabia Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.5.2.6. Saudi Arabia Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.5.2.7. Saudi Arabia Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.5.2.9. South Africa Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.5.2.10. South Africa Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.5.2.11. South Africa Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.5.2.13. Venezuela Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.5.2.14. Venezuela Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.5.2.15. Venezuela Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.5.2.17. Argentina Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.5.2.18. Argentina Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.5.2.19. Argentina Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.5.2.21. Rest of LAMEA Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.5.2.22. Rest of LAMEA Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.5.2.23. Rest of LAMEA Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user
7.5.3. LAMEA Continuous Glucose Monitoring Systems Market Size and Forecast, by Component
7.5.4. LAMEA Continuous Glucose Monitoring Systems Market Size and Forecast, by Demographics
7.5.5. LAMEA Continuous Glucose Monitoring Systems Market Size and Forecast, by End-user

Chapter 8: Company Profiles
8.1. Abbott Laboratories
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.2. A. Menarini Diagnostics S. R. L.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.3. Dexcom, Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Product Portfolio
8.3.4. Business Performance
8.3.5. Key Strategic Moves and Developments
8.4. Echo Therapeutics, Inc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.5. F. Hoffmann-La Roche Ltd.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.6. Glysens Incorporated
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Product Portfolio
8.6.4. Key Strategic Moves and Developments
8.7. Insulet Corporation
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Product Portfolio
8.7.4. Business Performance
8.7.5. Key Strategic Moves and Developments
8.8. Johnson & Johnson
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.9. Medtronic plc
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Senseonics Holdings, Inc.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves and Developments
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • A. Menarini Diagnostics
  • Abbott Laboratories
  • Dexcom Inc.
  • Echo Therapeutics Inc.
  • F. Hoffmann-La Roche Ltd
  • GlySens Incorporated
  • MORE
According to the report titled, 'Continuous Glucose Monitoring Systems Market by Component, Demographics, and End User:Opportunity Analysis and Industry Forecast, 2020-2027," the global continuous glucose monitoring systems market size was valued at $1.8 billion in 2019, and is projected to reach $8.8 billion by 2027, registering a CAGR of 22.0% during the forecast period.

The continuous glucose monitoring systems (CGMS) market has emerged as a promising diabetes management tool for monitoring all types of diabetic patients. Replacement/repeat sales of components such as sensors, drive the growth of the continuous glucose monitoring systems market. Continuous glucose monitoring systems are mainly used by patients suffering from hypo and hyperglycemic conditions.

Rise in incidences of diabetes worldwide, benefits of CGMS devices over POC glucometers, increase in awareness in developing and underdeveloped economies, and technological advancements with focus on developing CGMS devices majorly drive the continuous glucose monitoring systems market growth. FDA approval for the novel and innovative products such as artificial pancreas (dual-chambered investigational device that consists of a continuous glucose monitoring system, one insulin pump, and a control algorithm) would further drive the continuous glucose monitoring systems market trend. Continuous glucose monitoring systems are a more efficient monitoring and treatment alternative for patients with diabetes. However, lack of adequate reimbursement for devices is the key barrier to the adoption of the devices.

Among components, sensors market contributed for the highest continuous glucose monitoring systems market share generating the revenue of $1,174.87 million in 2019 and will generate the largest market revenue of $6,087.22 million by 2027. Sensors market is expected to have the highest growth CAGR at 22.6% during the analysis period. CGM sensors are changed at a very higher frequency as compared to transmitters and receivers due to the limited life span of 5 to 7 days. They need to be changed at least once a week, for proper glucose monitoring in the patient’s body. Thus, the sensors are purchased in bulk and very frequently by customers. Bulk purchase is preferred as the manufacturers offer discount to the customers.

Based on demographics, the continuous glucose monitoring systems market is bifurcated into adult and child population. According to IDF Atlas 7th edition, 4.72 billion adults and 1.92 billion children were diagnosed with diabetes in 2015. This number is expected to increase by 2040 and it is estimated that 9 billion adults and 6.16 billion children will be diagnosed with diabetes. As the percentage of adult population is high, it generated the largest market revenue of $1,758.74 million in 2019 and will register a CAGR of 22.0%. However, owing to the growth in demand for CGM devices for children, the children segment is expected to be the fastest growing segment, registering a CAGR of 22.9%.

Key Findings Of The Study

The sensors segment contributed to nearly two-thirds share of the global continuous glucose monitoring systems market in 2019.
The integrated insulin pumps segment is projected to grow at a significant CAGR of 22.4% from 2020 to 2027.
The ICUs segment is projected to grow at a significant CAGR of 21.6% during the forecast period.
Germany and France are the major shareholders, which collectively accounted for more than one-fourth share of the European continuous glucose monitoring systems market in 2019.
Japan was the major shareholder that accounted for more than one-fourth share of the Asia-Pacific continuous glucose monitoring systems market in 2019.
In 2019, North America was the highest contributor to the market in terms of revenue, owing to increase in wellness trend and early adoption of novel technologies. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period, owing to the presence of high populace countries such as India and China.

The key players operating in the global continuous glucose monitoring systems market include Abbott Laboratories, Dexcom, Inc., A. Menarini Diagnostics, Echo Therapeutics, Inc., GlySens Incorporated, Johnson & Johnson, Medtronic plc, Senseonics Holdings, Inc., and F. Hoffmann-La Roche Ltd.
Note: Product cover images may vary from those shown
4 of 5
  • Abbott Laboratories
  • Dexcom Inc.
  • A. Menarini Diagnostics
  • Echo Therapeutics Inc.
  • GlySens Incorporated
  • Johnson & Johnson
  • Medtronic plc
  • Senseonics Holdings Inc.
  • F. Hoffmann-La Roche Ltd
Note: Product cover images may vary from those shown
5 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll